Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe Fights To Regenerate Its Abandoned Pharma R&D Sites

Executive Summary

Last month's announcement that Pfizer Inc. plans to close its flagship U.K. R&D operations in Sandwich, Kent, is but the latest example of how major shifts in Big Pharma's business and research strategies are exacting a heavy toll on long-established facilities.

You may also be interested in...



U.K. Life Sciences Minister Faces Hurdles To Plans To Speed Drug Access

British life sciences minister George Freeman has launched ambitious plans to speed access to drugs by cutting drug development times by a third – but his plans face many hurdles.

NeRRe Therapeutics Spun Out Of GSK’s Unwanted Neuroscience Assets

The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.

Merck KGaA's Softly-Softly Approach To German Cutbacks Shows Learning From Swiss Experience

Merck KGaA is in learning mode as it calls for early retirements and voluntary redundancies in Germany, instead of more abrupt action. Around 10% of jobs at Merck KGaA in Germany are at risk, but the company will refrain from forced job losses until the end of 2017.

Related Content

Topics

UsernamePublicRestriction

Register

PS053178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel